Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Income from Continuing Operations (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Income from Continuing Operations for 11 consecutive years, with 77371000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 218.7% to 77371000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 136826000.0 through Dec 2025, down 274.75% year-over-year, with the annual reading at 130302000.0 for FY2025, 68.27% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 77371000.0 at Cartesian Therapeutics, down from 19518000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 14952000.0 in Q2 2024, with the low at 196658000.0 in Q4 2023.
  • Average Income from Continuing Operations over 5 years is 20358850.0, with a median of 13593000.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations surged 5505.67% in 2022, then plummeted 3437.15% in 2023.
  • Over 5 years, Income from Continuing Operations stood at 12239000.0 in 2021, then plummeted by 51.85% to 5893000.0 in 2022, then tumbled by 3437.15% to 196658000.0 in 2023, then surged by 87.66% to 24277000.0 in 2024, then crashed by 218.7% to 77371000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 77371000.0, 19518000.0, and 20063000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.